HUN Huntsman (HUN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Chemicals & allied products · CIK 0001307954
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
171
13F, latest reported quarter
What the filings say about HUN
Insiders, 180 days
+$981.0K net bought
1 buyer
Huntsman insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Huntsman CORP insiders bought a net $981.0K of stock across 12 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on May 7, 2025.
- -23.9% median (-22.8% mean) 90-day return after 4 previous buys.
- The trade is 1.4% of the 7,256,341 shares held after it.
- No other insider bought within 30 days.
- 171 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, President & CEO Huntsman Peter R bought about $981.0K of HUN on Aug 3, 2026, the largest insider purchase at the company on our record; 171 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 25.5% of the 116,914 shares held after it.
- No other insider bought within 30 days.
- 171 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Exec VP & CFO Lister Philip M. bought about $242.9K of HUN on Nov 10, 2025; 171 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on May 5, 2025.
- -30.1% median (-26.0% mean) 90-day return after 3 previous buys.
- The trade is 0.3% of the 6,600,227 shares held after it.
- No other insider bought within 30 days.
- 171 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, President & CEO Huntsman Peter R bought about $257.6K of HUN on May 7, 2025; 171 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on May 5, 2025.
- -30.1% median (-26.0% mean) 90-day return after 3 previous buys.
- The trade is 0.3% of the 6,577,227 shares held after it.
- No other insider bought within 30 days.
- 171 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, President & CEO Huntsman Peter R bought about $245.7K of HUN on May 7, 2025; 171 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 4, 2025.
- -30.1% median (-30.1% mean) 90-day return after 2 previous buys.
- The trade is 0.6% of the 6,555,227 shares held after it.
- No other insider bought within 30 days.
- 171 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, President & CEO Huntsman Peter R bought about $493.1K of HUN on May 5, 2025, the largest insider purchase at the company on our record; 171 funds added in the latest 13F quarter.12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$981.0K over 180 days
+$981.0K over 90 days
more than 87% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
171 funds bought in last quarter
more than 85% of Pharma & Biotech
Revenue
-5.8% year over year
below 63% of Pharma & Biotech
Margin
-5.0% net margin
more than 69% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
6.7% of the float short (float per yahoo 2026-10-27) · 3.9 days to cover · settled 2026-10-15
more than 58% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HUN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+3.7%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HUN: institutional holders (13F)
13F holdings, latest reported quarter
18,243,856 sh
$193.7M
9,166,098 sh
$97.3M
8,713,741 sh
$92.5M
7,594,395 sh
$80.7M
7,514,930 sh
$79.8M
Congress trades in HUN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Peter R. Huntsman
Activist 13D · 2026-02-20
5.09%
HUN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
HUN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
WPG Partners Select Small Cap Value Fund
$5.9M position · as of 2026-05-31
2.5%
Pzena Mid Cap Value Fund
$2.2M position · as of 2026-05-31
2.1%
WPG Partners Small Cap Value Diversified Fund
$616.5K position · as of 2026-05-31
1.7%
Pzena Small Cap Value Fund
$1.4M position · as of 2026-05-31
1.5%
Recurrent MLP & Energy Infrastructure Fund
$21.4M position · as of 2026-07-31
1.3%
ICON EQUITY INCOME FUND
$521.4K position · as of 2026-06-30
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Peter R. Huntsman
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$15.2M
$5.7M
$2.9M
+18%
+12%
2022
$13.4M
$9.7M
$3.2M
+24%
-4%
2021
$14.1M
$28.4M
$3.3M
+53%
+18%
2020
$13.5M
$12.3M
$3.0M
+8%
+8%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $981.0K bought by insiders over 180 days, 171 funds added last quarter. Each figure is a federal filing, dated the day it went public.
HUN financials
Revenue growth
-5.8%
XBRL, annual
Net margin
-5.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.7B
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM HUN
| FY Dec 2025 | $5.7B |
| FY Dec 2024 | $6.0B |
| FY Dec 2023 | $6.1B |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $8.5B |
| Mar 2026 | $1.4B |
| Dec 2025 | $1.4B |
| Sep 2025 | $1.5B |
| Jun 2025 | $1.5B |
| Mar 2025 | $1.4B |
| Dec 2024 | $1.5B |
| Sep 2024 | $1.5B |
| Jun 2024 | $1.6B |
At each fiscal year end
Single quarter
Net margin, TTM
-5.8%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM HUN
| FY Dec 2025 | -5.0% |
| FY Dec 2024 | -3.1% |
| FY Dec 2023 | +1.7% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +12.4% |
| Mar 2026 | -3.7% |
| Dec 2025 | -7.1% |
| Sep 2025 | -1.7% |
| Jun 2025 | -10.8% |
| Mar 2025 | -0.4% |
| Dec 2024 | -9.7% |
| Sep 2024 | -2.1% |
| Jun 2024 | +1.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$135.0M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM HUN
| FY Dec 2025 | $116.0M |
| FY Dec 2024 | $79.0M |
| FY Dec 2023 | -$21.0M |
| FY Dec 2022 | $642.0M |
| FY Dec 2021 | $626.0M |
| Mar 2026 | -$91.0M |
| Dec 2025 | $19.0M |
| Sep 2025 | $153.0M |
| Jun 2025 | $54.0M |
| Mar 2025 | -$110.0M |
| Dec 2024 | $102.0M |
| Sep 2024 | $88.0M |
| Jun 2024 | -$4.0M |
At each fiscal year end
Single quarter
Debt to equity
0.77x
long-term 2026-03-31 plus current 2026-03-31; equity 2026-03-31
Debt to equity HUN
| FY Dec 2025 | 0.73x |
| FY Dec 2024 | 0.62x |
| FY Dec 2023 | 0.52x |
| FY Dec 2022 | 0.48x |
| FY Dec 2021 | 0.35x |
| Mar 2026 | 0.77x |
| Dec 2025 | 0.73x |
| Sep 2025 | 0.73x |
| Jun 2025 | 0.72x |
| Mar 2025 | 0.66x |
| Dec 2024 | 0.62x |
| Sep 2024 | 0.60x |
| Jun 2024 | 0.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.15x
TTM operating cash flow over long-term 2026-03-31 plus current 2026-03-31
Cash flow to debt HUN
| FY Dec 2025 | 0.14x |
| FY Dec 2024 | 0.14x |
| FY Dec 2023 | 0.12x |
| FY Dec 2022 | 0.53x |
| FY Dec 2021 | 0.61x |
| Mar 2026 | 0.15x |
| Dec 2025 | 0.14x |
| Sep 2025 | 0.18x |
| Jun 2025 | 0.15x |
| Mar 2025 | 0.13x |
| Dec 2024 | 0.14x |
| Sep 2024 | 0.15x |
| Jun 2024 | 0.16x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-11.8%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity HUN
| FY Dec 2025 | -9.9% |
| FY Dec 2024 | -6.1% |
| FY Dec 2023 | +2.9% |
| FY Dec 2022 | +11.5% |
| FY Dec 2021 | +26.5% |
| Mar 2026 | -11.8% |
| Dec 2025 | -9.9% |
| Sep 2025 | -11.2% |
| Jun 2025 | -11.3% |
| Mar 2025 | -5.1% |
| Dec 2024 | -6.1% |
| Sep 2024 | -3.6% |
| Jun 2024 | -2.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-4.6%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets HUN
| FY Dec 2025 | -4.0% |
| FY Dec 2024 | -2.6% |
| FY Dec 2023 | +1.3% |
| FY Dec 2022 | +5.2% |
| FY Dec 2021 | +11.5% |
| Mar 2026 | -4.6% |
| Dec 2025 | -4.0% |
| Sep 2025 | -4.6% |
| Jun 2025 | -4.7% |
| Mar 2025 | -2.1% |
| Dec 2024 | -2.6% |
| Sep 2024 | -1.6% |
| Jun 2024 | -1.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital HUN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +10.1% |
| FY Dec 2021 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-3.4%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed HUN
| FY Dec 2025 | -2.4% |
| FY Dec 2024 | -0.4% |
| FY Dec 2023 | +1.3% |
| FY Dec 2022 | +9.7% |
| FY Dec 2021 | n/a |
| Mar 2026 | -3.4% |
| Dec 2025 | -2.4% |
| Sep 2025 | -2.4% |
| Jun 2025 | -1.8% |
| Mar 2025 | +0.9% |
| Dec 2024 | -0.4% |
| Sep 2024 | -0.3% |
| Jun 2024 | -0.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing HUN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 44.87x |
| FY Dec 2022 | 12.21x |
| FY Dec 2021 | 7.41x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$3.2B
market value at close 2026-10-26 on 2026-04-22 shares, plus long-term 2026-03-31 plus current 2026-03-31, minus cash 2026-03-31
Enterprise value HUN
| FY Dec 2025 | $3.3B |
| FY Dec 2024 | $4.6B |
| FY Dec 2023 | $5.5B |
| FY Dec 2022 | $6.4B |
| FY Dec 2021 | $8.1B |
| Mar 2026 | $4.0B |
| Dec 2025 | $3.3B |
| Sep 2025 | $3.1B |
| Jun 2025 | $3.4B |
| Mar 2025 | $4.4B |
| Dec 2024 | $4.6B |
| Sep 2024 | $5.7B |
| Jun 2024 | $5.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+8.7%
TTM free cash flow over market value at close 2026-10-26
FCF yield HUN
| FY Dec 2025 | +6.7% |
| FY Dec 2024 | +2.5% |
| FY Dec 2023 | -0.5% |
| FY Dec 2022 | +12.2% |
| FY Dec 2021 | +8.2% |
| Mar 2026 | +5.8% |
| Dec 2025 | +6.7% |
| Sep 2025 | +12.8% |
| Jun 2025 | +7.4% |
| Mar 2025 | +2.8% |
| Dec 2024 | +2.5% |
| Sep 2024 | +1.4% |
| Jun 2024 | +2.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing HUN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 4.29x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $5.7B | $6.0B | $6.1B | $8.0B |
| Gross profit | $751.0M | $866.0M | $906.0M | $1.5B |
| Operating income | -$131.0M | -$25.0M | $84.0M | $672.0M |
| Net income | -$284.0M | -$189.0M | $101.0M | $460.0M |
| EPS (diluted) | -1.65 | -1.10 | 0.57 | 2.27 |
| Operating cash flow | $289.0M | $263.0M | $209.0M | $914.0M |
| Cash | $429.0M | $340.0M | $540.0M | $654.0M |
| Long-term debt | $1.7B | $1.5B | $1.7B | $1.7B |
| Buybacks | $0 | $4.0M | $349.0M | $1.0B |
| Dividends paid | $146.0M | $174.0M | $169.0M | $171.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
HUN Stock Sonar score 6/7 axes
Find similar shapesCompareHUN ranks highest on profitability (79th percentile) and insider conviction (71st), and lowest on growth (37th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HUN filings, in plain words
Are Huntsman insiders buying or selling HUN?
In the 180 days to 2026-10-28, Huntsman insiders were net buyers, a net $981.0K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Huntsman insiders were net buyers of HUN, a net $981.0K across purchases and sales reported on Form 4 by 1 buyer. The latest 5% ownership filing is a 13D by Peter R. Huntsman, filed 2026-02-20, for 5.1% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
